Brief: MAIA Biotechnology Says New Responder In Non-Small Cell Lung Cancer Phase 2 Clinical Trial
05/06/2025 16:14
June 5 (Reuters) - Maia Biotechnology Inc MAIA.A: MAIA BIOTECHNOLOGY ANNOUNCES NEW RESPONDER IN NON-SMALL CELL LUNG CANCER PHASE 2 CLINICAL TRIAL MAIA BIOTECHNOLOGY INC - PARTIAL RESPONSE DEFINED AS DECREASE IN TUMOR SIZE OF AT LEAST 30% Source text: ID:nBw103Pw3a Further company coverage: MAIA.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale